Lucid Capital initiated coverage of Medicenna Therapeutics (MDNAF) with a Buy rating and C$4 price target
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDNAF:
- Promising Developments in Medicenna Therapeutics Corp’s ABILITY-1 Trial Justify Buy Rating
- Medicenna to Engage Investors at ROTH Healthcare Conference
- Medicenna Therapeutics Announces Shareholder Meeting Results and Leadership Updates
- Medicenna to Present at H.C. Wainwright Global Investment Conference